ClinicalTrials.Veeva

Menu

Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation (NEPAF)

A

Asociación para Evitar la Ceguera en México

Status and phase

Terminated
Phase 2

Conditions

Macular Edema
Macular Thickening

Treatments

Other: Lubricant
Drug: Nepafenac

Study type

Interventional

Funder types

Other

Identifiers

NCT00801905
NEPAFENACO
NEPAFENAC IN PRFC

Details and patient eligibility

About

The purpose of this study is to determine whether topical nepafenac (qid) is effective in preventing and treating macular thickening related pan-retinal photocoagulation in patients with diabetic retinopathy.

Full description

Objective: To evaluate the effect of topical nepafenac 0.1 %, in preventing and in treating macular thickening related to pan-retinal photocoagulation in diabetic patients. Material and methods: This is a prospective, longitudinal, and controlled study in patients with diabetic retinopathy (severe non-proliferative and proliferative retinopathy), with a symmetric severity in both eyes and without a clinical significant macular edema. The best corrected visual acuity (BCVA) in all patients was 20/80 or better. All patients will undergo pan-retinal photocoagulation in three different sessions (with 2 weeks in apart between them). Each patient will receive topical nepafenac 0.1% (qid) on one eye, and placebo (qid) at the fellow eye, starting 1 week before the first retinal photocoagulation session and continued for 9 weeks ( ending 4 weeks after pan-retinal photocoagulation is completed). Spectral domain OCT and BCVA in ETDRS scale will be performed before and at 2 weeks after each laser session, and at 1, 2 and 3 months after treatment completed. BCVA and OCT outcomes of each studied period will be compared on both eyes, and side effects will be recorded.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with Severe and proliferative Diabetic Retinopathy
  • Symmetric severity grade on both eyes
  • Best corrected visual acuity better than 20/80

Exclusion criteria

  • Clinical significant macular edema
  • Lens opacity
  • Ocular surgery 6 months or less before recruit
  • Uveitis history
  • Actual use of topical or systemic non-steroidal anti inflammatory agents
  • Actual or history of other macular diseases
  • Ocular surface diseases
  • Vitreomacular traction syndrome
  • Other vascular retinal diseases different to diabetic retinopathy
  • Actual or history of use of topical prostaglandin analogues

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

50 participants in 2 patient groups, including a placebo group

1: Nepafenac
Active Comparator group
Description:
Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
Treatment:
Drug: Nepafenac
2: placebo
Placebo Comparator group
Description:
Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
Treatment:
Other: Lubricant

Trial contacts and locations

2

Loading...

Central trial contact

Dulce O Rascon-Vargas, Fellow

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems